Search
Setiptiline
go.drugbank.com/drugs/DB09304ExperimentalIn Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Coproporphyrin I
go.drugbank.com/drugs/DB03727ExperimentalCategories: Heterocyclic Compounds with 4 or More RingsDiacetyldeuteroheme
go.drugbank.com/drugs/DB03418ExperimentalCategories: Heterocyclic Compounds with 4 or More RingsCHGN111
go.drugbank.com/drugs/DB06376ExperimentalNumerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.
Setileuton
go.drugbank.com/drugs/DB19550InvestigationalSetileuton is under investigation in clinical trial NCT00404313 (The Effect of MK0633 in Patients With Chronic Asthma (0633-007)). Setileuton has a monoisotopic molecular weight of 463.12 Da. … The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory.
Felezonexor
go.drugbank.com/drugs/DB21067InvestigationalFelezonexor has a monoisotopic molecular weight of 419.12 Da. … The usage of the INN stem '-nexor' in the name indicates that Felezonexor is a nuclear export inhibitor.
Icovamenib
go.drugbank.com/drugs/DB21669InvestigationalIcovamenib is under investigation in clinical trial NCT06152042 (Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus). Icovamenib has a monoisotopic molecular weight of 566.28 Da. … The usage of the INN stem '-menib' in the name indicates that Icovamenib is a menin interaction inhibitor.
Calusterone
go.drugbank.com/drugs/DB01564ExperimentalIllicitA Schedule IV drug in Canada.
Synonyms: 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one, 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-oneRanosidenib
go.drugbank.com/drugs/DB21727InvestigationalRanosidenib has a monoisotopic molecular weight of 453.12 Da. … Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).
Pipequaline
go.drugbank.com/drugs/DB13991ExperimentalIt presents a unique chemical structure that does not follow the structural properties of other drugs of its class. … However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic or anticonvulsant effect.